Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05643196 · ClinicalTrials.gov registry record · Phase 2

Focused Ultrasound Modulation of the Globus Pallidus Interna in Schizophrenia

A Phase 2 study of Schizophrenia and Schizophrenia Schizoaffective, sponsored by NYU Langone Health.

Completed
Registry status
Phase 2
Development phase
15
Enrollment target
2
Study locations

NCT05643196: Completed Phase 2 study of Schizophrenia and Schizophrenia Schizoaffective, sponsored by NYU Langone Health.

NCT05643196 is a Phase 2 study of Schizophrenia and Schizophrenia Schizoaffective that has completed, run by NYU Langone Health. The registered enrollment target is 15 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05643196, a Phase 2 study of Schizophrenia and Schizophrenia Schizoaffective, has completed, sponsored by NYU Langone Health.

COMPLETED
Registry status
Phase 2
Development phase
15 participants
Enrollment target
2
Study locations

Study Summary

This is a single-site, phase 2, sham-controlled random-order cross-over pilot trial of PLIFUS targeting the right GPi in individuals with schizophrenia. Twelve individuals with schizophrenia who report continuous hallucinations or delusions of mild or greater severity will receive one session of PLIFUS and one session of sham PLIFUS in random order, one week apart. If no effect of PLIFUS is detected on measures of functional connectivity or psychotic symptoms in the first four completers, the trial will be changed to 3 sessions of PLIFUS or sham administered over 5 days.

Primary Outcome

Change in GPi functional connectivity measured via functional MRI (fMRI) captured pre-sonication and 10 minutes post-sonication during the PLIFUS intervention visit.

Interventions

  • DEVICE MRI
  • DEVICE PLIFUS
  • DEVICE Sham PLIFUS

Study Locations (2)

New York

  • NYU Langone Brooklyn - Brooklyn
  • NYU Langone Health - New York

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2023-04-06
Est. Completion 2024-04-01
Phase Phase 2
NYU Langone Health

1,164 total trials

What the finished NCT05643196 record still lists

NCT05643196 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (93% lower).

The record links to 2 conditions, with Schizophrenia appearing as the primary indexed condition, and to 3 interventions - of which MRI is the first listed.

NCT05643196 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT05643196 about?

NCT05643196 is a clinical study titled "Focused Ultrasound Modulation of the Globus Pallidus Interna in Schizophrenia". This is a single-site, phase 2, sham-controlled random-order cross-over pilot trial of PLIFUS targeting the right GPi in individuals with schizophrenia. Twelve individuals with schizophrenia who report continuous hallucinations or delusions of mild or greater severity will receive one session of PLI...

What is the current status of trial NCT05643196?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2023-04-06. Estimated completion is 2024-04-01.

What conditions does trial NCT05643196 study?

This clinical trial studies the following conditions: Schizophrenia, Schizophrenia Schizoaffective.

What interventions are being tested in trial NCT05643196?

The interventions under investigation include: MRI (DEVICE), PLIFUS (DEVICE), Sham PLIFUS (DEVICE).

Who is sponsoring clinical trial NCT05643196?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05643196 being conducted?

This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05643196's enrollment target sits among peer trials

15 301st of 315 higher than 13 of 315 other Schizophrenia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01889381 · 15 participants · Phase 2

    Human Craniomaxillofacial Allotransplantation

  • NCT02530073 · 15 participants · NA

    Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

  • NCT02535936 · 15 participants · NA

    Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

  • NCT02918474 · 15 participants · NA

    Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05643196, the US trial registry maintained by the National Library of Medicine. NCT05643196 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.